Japan Biotech Forum: London 2010.
The Japan Biotech Forum, held in London, included topics covering new licensing developments in the Japanese pharma and biotech industries. This conference report highlights selected presentations on licensing opportunities from several Japanese companies, including CanBas, LivTech, REGiMMUNE, D Western Therapeutics Institute and Chiome Bioscience. Investigational drugs discussed include CBP-501 (CanBas), LIV-2008 (LivTech), RGI-2001 (REGiMMUNE), IVX-214 (D Western Therapeutics Institute/ Nippon Shinyaku) and anti-Sema 3A (Chiome Bioscience).
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. asma.al-shamahi@thomsonreuters.com
Asma
A
Al-Shamahi
D000818:Animals; D001709:Biotechnology / Q000191:economics / Q000458:organization & administration*; D003132:Commerce; D016503:Drug Delivery Systems; D015195:Drug Design; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration*; D015507:Drugs, Investigational / Q000494:pharmacology; D006801:Humans; D007564:Japan
D015507:Drugs, Investigational